Compare YI & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YI | IXHL |
|---|---|---|
| Founded | 2010 | 2001 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.1M | 49.1M |
| IPO Year | N/A | N/A |
| Metric | YI | IXHL |
|---|---|---|
| Price | $3.61 | $0.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.3K | ★ 24.0M |
| Earning Date | 12-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,979,883,442.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.19 | $0.08 |
| 52 Week High | $11.35 | $2.25 |
| Indicator | YI | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 38.01 | 55.34 |
| Support Level | $3.60 | $0.35 |
| Resistance Level | $3.95 | $0.50 |
| Average True Range (ATR) | 0.22 | 0.04 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 51.22 | 59.53 |
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.